These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 21857810)

  • 1. Serological testing versus other strategies for diagnosis of active tuberculosis in India: a cost-effectiveness analysis.
    Dowdy DW; Steingart KR; Pai M
    PLoS Med; 2011 Aug; 8(8):e1001074. PubMed ID: 21857810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serological tests for the diagnosis of active tuberculosis: relevance for India.
    Steingart KR; Ramsay A; Dowdy DW; Pai M
    Indian J Med Res; 2012 May; 135(5):695-702. PubMed ID: 22771604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and Consequences of Using Interferon-γ Release Assays for the Diagnosis of Active Tuberculosis in India.
    Little KM; Pai M; Dowdy DW
    PLoS One; 2014; 10(4):e0124525. PubMed ID: 25918999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the patient and health system impacts of alternative xpert® MTB/RIF algorithms for the diagnosis of pulmonary tuberculosis in Addis Ababa, Ethiopia.
    Tesfaye A; Fiseha D; Assefa D; Klinkenberg E; Balanco S; Langley I
    BMC Infect Dis; 2017 May; 17(1):318. PubMed ID: 28464797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact and cost-effectiveness of culture for diagnosis of tuberculosis in HIV-infected Brazilian adults.
    Dowdy DW; Lourenço MC; Cavalcante SC; Saraceni V; King B; Golub JE; Bishai D; Durovni B; Chaisson RE; Dorman SE
    PLoS One; 2008; 3(12):e4057. PubMed ID: 19129940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid vs. solid culture for tuberculosis: performance and cost in a resource-constrained setting.
    Chihota VN; Grant AD; Fielding K; Ndibongo B; van Zyl A; Muirhead D; Churchyard GJ
    Int J Tuberc Lung Dis; 2010 Aug; 14(8):1024-31. PubMed ID: 20626948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid, point-of-care diagnosis of tuberculosis with novel Truenat assay: Cost-effectiveness analysis for India's public sector.
    Lee DJ; Kumarasamy N; Resch SC; Sivaramakrishnan GN; Mayer KH; Tripathy S; Paltiel AD; Freedberg KA; Reddy KP
    PLoS One; 2019; 14(7):e0218890. PubMed ID: 31265470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed diagnosis and treatment of tuberculosis in HIV+ patients in Mozambique: A cost-effectiveness analysis of screening protocols based on four symptom screening, smear microscopy, urine LAM test and Xpert MTB/RIF.
    Orlando S; Triulzi I; Ciccacci F; Palla I; Palombi L; Marazzi MC; Giuliano M; Floridia M; Mancinelli S; Mutemba E; Turchetti G
    PLoS One; 2018; 13(7):e0200523. PubMed ID: 30024890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimating TB diagnostic costs incurred under the National Tuberculosis Elimination Programme: a costing study from Tamil Nadu, South India.
    Muniyandi M; Lavanya J; Karikalan N; Saravanan B; Senthil S; Selvaraju S; Mondal R
    Int Health; 2021 Dec; 13(6):536-544. PubMed ID: 33570132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trade-offs between cost and accuracy in active case finding for tuberculosis: A dynamic modelling analysis.
    Cilloni L; Kranzer K; Stagg HR; Arinaminpathy N
    PLoS Med; 2020 Dec; 17(12):e1003456. PubMed ID: 33264288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis.
    Dowdy DW; O'Brien MA; Bishai D
    Int J Tuberc Lung Dis; 2008 Sep; 12(9):1021-9. PubMed ID: 18713499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Smear plus Detect-TB for a sensitive diagnosis of pulmonary tuberculosis: a cost-effectiveness analysis in an incarcerated population.
    Schmid KB; Scherer L; Barcellos RB; Kuhleis D; Prestes IV; Steffen RE; Dalla Costa ER; Rossetti ML
    BMC Infect Dis; 2014 Dec; 14():678. PubMed ID: 25510328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis.
    Steingart KR; Flores LL; Dendukuri N; Schiller I; Laal S; Ramsay A; Hopewell PC; Pai M
    PLoS Med; 2011 Aug; 8(8):e1001062. PubMed ID: 21857806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review.
    Steingart KR; Henry M; Laal S; Hopewell PC; Ramsay A; Menzies D; Cunningham J; Weldingh K; Pai M
    PLoS Med; 2007 Jun; 4(6):e202. PubMed ID: 17564490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis of LED fluorescence microscopy in the diagnosis of pulmonary tuberculosis in Indian settings.
    Kelly V; Sagili KD; Satyanarayana S; Reza LW; Chadha SS; Wilson NC
    Int J Tuberc Lung Dis; 2015 Jun; 19(6):696-701. PubMed ID: 25946362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of diagnostic algorithms including lateral-flow urine lipoarabinomannan for HIV-positive patients with symptoms of tuberculosis.
    Yakhelef N; Audibert M; Ferlazzo G; Sitienei J; Wanjala S; Varaine F; Bonnet M; Huerga H
    PLoS One; 2020; 15(1):e0227138. PubMed ID: 31999746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role and performance of chest X-ray for the diagnosis of tuberculosis: a cost-effectiveness analysis in Nairobi, Kenya.
    van Cleeff MR; Kivihya-Ndugga LE; Meme H; Odhiambo JA; Klatser PR
    BMC Infect Dis; 2005 Dec; 5():111. PubMed ID: 16343340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis.
    Vassall A; van Kampen S; Sohn H; Michael JS; John KR; den Boon S; Davis JL; Whitelaw A; Nicol MP; Gler MT; Khaliqov A; Zamudio C; Perkins MD; Boehme CC; Cobelens F
    PLoS Med; 2011 Nov; 8(11):e1001120. PubMed ID: 22087078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis of microscopic observation drug susceptibility test versus Xpert MTB/Rif test for diagnosis of pulmonary tuberculosis in HIV patients in Uganda.
    Walusimbi S; Kwesiga B; Rodrigues R; Haile M; de Costa A; Bogg L; Katamba A
    BMC Health Serv Res; 2016 Oct; 16(1):563. PubMed ID: 27724908
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.